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We describe a 16-year-old boy with rhabdomyosarcoma, consistent with embryonal subtype, of the lower extremity who
received systemic neoadjuvant chemotherapy and subsequent excision. Microscopic sections of the postchemotherapy excision
demonstrated diffuse, prominent, and immature adipocyte-like differentiation, in addition to skeletal muscle differentiation.
Adipocyte-like differentiation was confirmed by a combination of positive Oil Red O and adipophilin immunohistochemical
staining. To our knowledge, this represents the first report of an unusual phenomenon of differentiation of a soft tissue
rhabdomyosarcoma into adipocyte-like cells after chemotherapy.
1. Introduction
Rhabdomyosarcoma is an aggressive mesenchymal neo-
plasm, most common in children, that frequently requires
multimodality therapy consisting of surgery and chemother-
apy [1]. So-called “cytodifferentiation” after neoadjuvant
chemotherapy is a well-described phenomenon in rhab-
domyosarcoma and consists of more prominent rhabdomy-
oblasts and decreased primitive, proliferating cells [2–4].
Rhabdomyosarcoma with adipocyte-like cells has been rarely
observed in unusual ovarian carcinosarcomas [5]. However,
to our knowledge, the present case represents the first
example of a soft tissue rhabdomyosarcoma with adipocyte-
like cells after chemotherapy.
2. Case Presentation
One year prior to presentation, a 16-year-old boy with no sig-
nificant medical history noticed a lump, which progressively
enlarged over the course of several months, at his posterior
left knee. Magnetic resonance imaging demonstrated a 13-
centimeter mass in the left posteroinferior thigh, centered in
the region of the semitendinosusmuscle and extending to the
long head of the biceps femoris muscle.
A fine-needle aspiration of the tumor demonstrated a
heterogeneous population of ovoid to tapered spindled cells
with variable amounts of densely eosinophilic cytoplasm and
occasional multinucleated cells (Figure 1(a)). No lipogenic
differentiation was noted on any of the smears or cell block.
Immunohistochemical stains for desmin (Figure 1(b)) and
myogenin (Figure 1(c)) were positive, whereas staining for
CD68, keratin, S-100, SOX-10, HMB-45, and Melan-A was
negative (not shown). A diagnosis of rhabdomyosarcomawas
made. Fluorescence in situ hybridization was negative for a
FOXO1 13q14 rearrangement. Based on the cytomorphology
and lack of FOXO1 rearrangement, an embryonal subtype
was favored. He received chemotherapy per intermediate risk
protocol ARST0531 with vincristine/irinotecan for 10 weeks.
Following chemotherapy, the tumor was completely
excised. Grossly, the mass was mixed, cystic and solid,
and separated from the surrounding skeletal muscle by a
thin white capsule (Figure 1(d)). Routine hematoxylin and
eosin (H&E) sections demonstrated diffuse sheets of round
tumor cells with variable amounts of dense, eosinophilic
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Figure 1: Gross andmicroscopic findings. (a) Hematoxylin and eosin (H&E) stain from fine-needle aspiration sample, prior to chemotherapy
treatment, reveals a heterogeneous population of ovoid to slightly spindled cells (H&E, ×100 original magnification), (b) a subset of tumor
cells are positive for desmin immunostain (×400 original magnification), and (c) most tumor cells are positive for myogenin (myogenin
immunostain, ×400 original magnification). (d) Gross appearance of resected tumor after adjuvant chemotherapy treatment.
rhabdomyoblastic cytoplasm with large nuclei (Figure 2(a)).
Diffusely throughout all sections of the tumor, a subset of
cells showed a spectrum of vacuolation. The vacuolation
ranged from small intracytoplasmic vacuoles to cells with
multiple vacuoles indenting the nucleus thereby resem-
bling adipocytes or lipoblasts (Figure 2(b)). The vacuolated
cells were positive for adipophilin (Figure 2(c)), Oil Red O
(Figure 2(d)), and S-100 protein (Figure 2(e)). Adipophilin is
a ubiquitous component of lipid droplets and is a specific
marker for lipid accumulation, which has been reported
in cells of lactating mammary epithelium, adrenal cortex,
male reproductive system (Sertoli and Leydig cells), steatotic
hepatocytes in alcoholic cirrhosis, and liposarcomas [6].
The vacuoles in the adipocyte-like cells did not stain with
periodic acid-Schiff, with or without diastase (not shown).
An immunostain for desmin demonstrated staining within
the cytoplasm of adipocyte-like cells (Figure 2(f)), while
immunostaining formyogeninwas negative within the nuclei
of adipocyte-like cells (Figure 2(g)). Table 1 lists the anti-
body sources and dilutions used. Cystic change, scattered
histiocytes, and extracellular hemosiderin consistent with
treatment effect were also present. Mitotic activity was low
(1 mf/10 hpf). No coagulative necrosis was identified.
3. Discussion
Rhabdomyosarcoma is the most common soft tissue malig-
nancy in children and adolescents and consists of a biologi-
cally and genetically diverse group of sarcoma [7]. Standard
Table 1: Antibody sources and dilutions.
Antibody Source Clone Dilution
Adipophilin Cell Marque,Rocklin, CA Polyclonal Undiluted
Desmin Cell Marque D33 1 : 5
Myogenin Cell Marque F5D Undiluted
S-100 protein DAKO,Carpinteria, CA Polyclonal 1 : 2000
treatment regimens for rhabdomyosarcoma include local
control with surgery or radiation therapy in conjunction
with multiagent chemotherapy [1]. When the tumor is locally
advanced, most protocols recommend a biopsy followed by
neoadjuvant chemotherapy prior to excision [8].
Several studies have described the range of microscopic
treatment related changes in rhabdomyosarcoma. Nonspe-
cific treatment effect, such as necrosis, macrophage infiltrate,
fibrosis, and skeletal muscle atrophy are commonly observed.
A decrease in proliferative activity is also often present [9].
Rhabdomyosarcoma can also undergo histologic differentia-
tion after treatment. Specifically, rhabdomyoblasts and strap
cells become more prominent [2] while undifferentiated,
primitive round cells become less conspicuous. Some authors
have suggested that these apparently differentiated neoplas-
tic cells may represent terminally differentiated elements
withdrawn from the cell cycle after chemotherapy [10].
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Figure 2: Histochemical and immunohistochemical studies in posttreatment rhabdomyosarcoma. (a) Microscopic appearance of resected
tumor after adjuvant chemotherapy, demonstrating diffuse sheets of round tumor cells (H&E,×200 originalmagnification) and (b) vacuolated
adipocyte-like cells (H&E, ×400 original magnification). (c) Adipophilin demonstrates strong membrane staining within adipocyte-like cells
(adipophilin immunostain, ×100 original magnification). (d) Oil Red O histochemical stain highlights intracytoplasmic lipid within the
adipocyte-like cells (Oil RedO,×200 originalmagnification). (e)The adipocyte-like cells stainwith S-100 protein (S-100 protein immunostain,
×400 original magnification). (f) A subset of vacuolated adipcoyte-like cells show focal cytoplasmic desmin positivity (desmin immunostain,
×400 original magnification) but myogenin (g) is negative in vacuolated cells, staining only the nuclei of rhabdomyoblasts (myogenin
immunostain, ×400 original magnification).
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The presence of so-called postchemotherapy “cytodiffer-
entiation” is thought to be more frequent in embryonal
and botryoid rhabdomyosarcoma than other subtypes [3,
4].
In addition to the phenomenon of cytodifferentiation,
vacuolated cells have been previously noted in cases of treated
rhabdomyosarcoma. Coffin et al. described the presence of
vacuolated cells in a rhabdomyosarcoma [9]. Likewise, a
case report of an ovarian carcinosarcoma with pleomorphic
rhabdomyosarcomatous differentiation noted the presence
of “pseudolipoblasts” after neoadjuvant chemotherapy [5].
The presence of cells with morphology intermediate between
rhabdomyoblasts and multivacuolated adipocyte-like cells
suggested that the chemotherapy induced differentiation in
the rhabdomyosarcomatous component of the carcinosar-
coma, representative of a posttreatment phenomenon [5].
In our differential diagnosis, we also considered the
possibility of clear cell rhabdomyosarcoma, or glycogen-rich
rhabdomyosarcoma [11]. However, several lines of evidence
argue against this possibility. First, clear cell rhabdomyosar-
coma has not been reported as a treatment related change.
Second, the histochemical and immunohistochemical fea-
tures of the posttreatment excision support lipid accumu-
lation rather than glycogen in the vacuolated cells. Rare
examples of lipid-rich rhabdomyosarcomas have also been
described, in untreated tumors but not as a morphologic
change induced by chemotherapy [12, 13]. The presence of S-
100 protein immunostaining, though not highly specific, is
at least supportive of adipocytic differentiation. Furthermore,
regenerating skeletal muscle can mimic rhabdomyosarcoma
and sometimes demonstrate vacuolation. However, in the
present case, the resection lacks other characteristic fea-
tures of muscle regeneration such as sarcolemmal ghosts or
necrotic myofibers [14]. We also considered the possibility
that lipogenic differentiation was already present, but not
sampled, in the FNA biopsy. Although it is impossible to
completely exclude this possibility, the FNAyielded abundant
cells using a “cone biopsy” technique that samples multiple
regions of tumor [15, 16]. Yet, the biopsy contained no
vacuolated cells whereas such cells were present diffusely in
every section of the excision specimen. Finally, the decrease
in density of myogenin positive cells after chemotherapy
suggests a different expression pattern in the posttreated
tumor compared to the pretreatment biopsy.
Rhabdomyoblastic differentiation is well described in a
variety of mesenchymal tumors, including malignant mixed
Mullerian tumors of the uterus and carcinosarcomas, as well
as neuroectodermal neoplasms such as malignant Triton
tumor or medulloblastomas. Intriguingly, rhabdomyoblastic
differentiation has been reported in liposarcoma [17, 18],
but the reverse (i.e., differentiation of rhabdomyoblasts into
lipoblasts or adipocytes) appears extremely rare. Adipocyte-
like cells have been previously reported in a primary ovarian
rhabdomyosarcoma [19]. Recent cell culture studies suggest
that rhabdomyosarcomas can arise from adipocyte pro-
genitors via Smd activation, providing a model whereby
embryonal rhabdomyosarcoma can arise in sites devoid of
skeletal muscle [20]. Lineage tracing and clonal analysis
studies have demonstrated that adult skeletal muscle stem
cells are bipotential and can give rise to brown adipogenic and
myogenic progenitors presumably under the correct genetic
and epigenetic mechanisms [21].
To our knowledge, this is the first reported case of
a soft tissue rhabdomyosarcoma with evidence to support
adipocyte-like cells as a posttreatment phenomenon and
expand the spectrum of cytodifferentiation that can be
observed in treated rhabdomyosarcoma.
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